Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval
Related Experiment Videos
G L Kearns1, R A Young, R F Jacobs
1Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.
Insights
New cefotaxime dosing regimens (75 mg/kg every 8 or 12 hours) may be effective for pediatric infections, potentially reducing administration frequency without compromising safety or efficacy.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Therapy
Background:
- Cefotaxime, a third-generation cephalosporin, is a first-line antibiotic for pediatric infections.
- Current dosing (50 mg/kg every 6 hours) reflects its short elimination half-life.
- Alternative regimens require evaluation for improved therapeutic outcomes.
Purpose of the Study:
- To re-examine pediatric pharmacokinetic data for cefotaxime.
- To simulate alternative dosing regimens for cefotaxime in children.
- To assess the potential efficacy and safety of modified cefotaxime dosing.
Main Methods:
- Analysis of pediatric pharmacokinetic data for cefotaxime.
- Pharmacokinetic simulations of multiple-dose regimens.
- Review of medical literature and clinical studies on cefotaxime use in pediatrics.
Main Results:
- Simulations suggest 75 mg/kg of cefotaxime every 8 or 12 hours can achieve adequate serum concentrations.
- These concentrations are projected to be effective against common pediatric pathogens.
- Literature review supports the clinical utility of less frequent dosing schedules.
Conclusions:
- Alternative cefotaxime dosing regimens (75 mg/kg every 8 or 12 hours) show promise for pediatric use.
- Less frequent administration may be possible without compromising safety or efficacy.
- Further clinical evaluation is recommended before widespread adoption of new regimens.
Abstract:
Cefotaxime is a third generation cephalosporin antimicrobial agent which has received wide acceptance as a first-line antibiotic for many infections in neonates, infants and children. With an average elimination half-life of about 1 h, cefotaxime is not considered to be a 'long half-life cephalosporin' like ceftriaxone. For this reason, currently accepted dosage regimens for cefotaxime in infants and children employ a dosage of 50 mg/kg every 6 h. Re-examination of the paediatric pharmacokinetic data for cefotaxime and use of simple multiple-dose pharmacokinetic simulation of alternative dosage regimens was performed. From this analysis, regimens administering 75 mg/kg of the drug every 8 h or every 12 h were projected to produce serum cefotaxime concentrations adequate to effectively kill many of the common pathogens against which the drug is currently indicated for use in children. The clinical utility of these alternative dosage regimens was supported by a review of the medical literature and examination of the clinical results from studies in neonates, infants and children where cefotaxime was administered in 2 to 3 divided doses daily. It would appear, therefore, that increasing the cefotaxime dosage to 75 mg/kg administered at 8 h intervals would result in less frequent drug administration which would not be expected to compromise safety and efficacy. Alternative dosage regimens for cefotaxime merit further consideration and clinical evaluation before they become commonly used in paediatric therapeutics.